Association of the intermediate filament nestin with cancer stage: a meta-analysis based on 223 positive/high nestin cases and 460 negative/low case-free controls

Beilong Zhong\textsuperscript{1,*}, Tao Wang\textsuperscript{2,3,*}, Jianyong Zou\textsuperscript{4,5,*}, Fangfang Zheng\textsuperscript{6}, Rijiao Huang\textsuperscript{7}, Xiaobin Zheng\textsuperscript{8}, Weilin Yang\textsuperscript{9} and Zhenguang Chen\textsuperscript{4,5,9,*}

\textsuperscript{1} Department of Thoracic Surgery, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China
\textsuperscript{2} Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen University, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Guangzhou, Guangdong, China
\textsuperscript{3} Department of Biochemistry, Zhongshan Medical School, Sun Yat-sen University, Guangzhou, Guangdong, China
\textsuperscript{4} Department of Thoracic Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
\textsuperscript{5} Lung Cancer Research Center of Sun Yat-sen University, Guangzhou, Guangdong, China
\textsuperscript{6} Department of Pediatrics, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China
\textsuperscript{7} Department of Clinical Laboratory, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China
\textsuperscript{8} Department of Respiratory Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong, China
\textsuperscript{9} Department of Cardiothoracic Surgery of East Division, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China

\textsuperscript{*} These authors have contributed equally to this work

Correspondence to: Zhenguang Chen, email: chenzhenguang@yahoo.com

Keywords: nestin, intermediate filament, cancer stage, TNM staging, meta-analysis

Received: February 28, 2015 Accepted: April 20, 2015 Published: May 08, 2015

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Background: Nestin, a member of the intermediate filament protein family, has been reported to be associated with several types of neoplastic transformation. However, questions remain, with studies reporting sometimes inconclusive or conflicting data. Thus, the aim of this study was to evaluate literature reports on the relationship between nestin and cancer stage.

Methods: Relevant articles published as of June 2014 were retrieved from multiple databases. After applying specific inclusion criteria, we chose seven articles relating to nestin expression and cancer stage, which included a total of 223 positive/high nestin cases and 460 negative/low case-free controls.

Results: Overall, positive/high nestin was significantly associated with median or advanced stages of several types of cancer (nestin and cancer stage: OR = 1.90, 95% CI = 1.30–2.78; nestin and lymph node: OR = 2.17, 95% CI = 1.26–3.72). Notably, studies relating to lung cancer (three qualifying articles) showed a significant association between nestin and lung cancer stage (OR = 2.00, 95% CI = 1.16–3.44).

Conclusion: These findings indicate that positive/high nestin may be more strongly linked to median or advanced cancer stage and correlated with malignant characteristics that lead to poor prognosis in different cancers, especially lung cancer.

INTRODUCTION

Nestin, a member of the class VI intermediate filament protein family, is expressed in normal cells of different tissues and organs.[3] Nestin expression was first reported in progenitor cells of central and peripheral nervous systems.[4] Its expression has since been reported in skeletal and cardiac muscle progenitors, developing tooth buds, testis and hair follicle sheath progenitor cells of the skin, a distribution that suggests that nestin is a
potential indicator of proliferative and multipotency status in several types of progenitor cells.[5, 6-11]

Recent reports have indicated that nestin might be linked to malignant characteristics, suggesting that abundant nestin expression correlates with greater malignancy and poorer prognosis in different cancers. Moreover, several studies have also reported that nestin is a marker of cancer stem cells in different malignancies, including brain tumors, uterine cancer, cervical cancer, prostate cancer, bladder cancer, head and neck cancer, ovarian cancer, testicular cancer, pancreatic cancer, and malignant rhabdoid tumors.[12-19]

The TNM (primary Tumor, lymph Nodes, and distant Metastasis) classification system, published by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC) for Malignant Tumors, has been used worldwide and across all medical specialties as a cancer-staging technique.[1] The TNM system is based on the anatomic extent of the tumor, as determined clinically and, in most instances, histopathologically, and can facilitate diagnosis, prognosis, treatment and other clinical decisions. [1, 2]

Although several articles on the relationship between nestin and cancer stage have been reported, including Masao et al.,[20] Shinichiro et al.,[21] Chen et al.[22-23] and Karsten et al.[24], only that of Karsten et al. reported that high nestin was strongly, and significantly, associated with cancer stage. Because of the relatively small sample sizes and limited statistical power of these individual, inconclusive studies, it is important to summarize the results from different studies to more accurately assess the association of positive/high nestin with cancer stage. To this end, we carried out a meta-analysis of all eligible studies, combining results to produce a single estimate of the major effect with enhanced precision.[25] We further performed a subgroup analysis stratified according to lymph node involvement and cancer category.

RESULTS

Study characteristics

Our search strategy identified 150 potentially relevant studies. After checking the title and abstract, a total of 30 articles consistent with our search criteria were preliminarily chosen for further detailed evaluation. After careful screening, we excluded 16 studies because data were insufficient for analysis. Of the remaining 14 studies, seven did not focus on nestin and cancer staging. Ultimately, seven studies on nestin and cancer staging that included a total of 223 positive/high nestin cases and 460 negative/low case-free controls were deemed eligible for the final analysis. The characteristics of the included studies are listed in Table 1. All studies were related to clinical research, including three lung cancer studies, one pancreatic cancer study, one prostate cancer study, one gastric adenocarcinoma study, and one oral cancer study. All cancers were confirmed pathologically. The study selection process is shown schematically in Figure 1.

Meta-analysis results

The frequency of tumors, lymph node involvement, and cancer stage in positive/high and negative/low nestin patients are shown in detail in Table 2. All TNM staging data were collected, and a subset of lymph node data was extracted.

Seven articles that included a total of 223 cases and 460 controls were used to evaluate the relationship between nestin with cancer stage. The main results of this meta-analysis are indicated in Figure 2. Overall, there was evidence for an association between positive/high nestin and median/advanced cancer stage in different cancers when all eligible studies were pooled into the meta-analysis. As show in Figure 2, the significant main effect observed was for nestin and median/advanced cancer stage (positive/high nestin vs. negative/low nestin: OR = 1.90, 95% CI = 1.30–2.78, P = 0.0009).

Four articles that included 110 cases and 277 controls were used to evaluate the relationship between nestin and lymph node involvement. In the analysis stratified by lymph node involvement (N0 vs. N1-3), as shown in Figure 4, the main effect remained (positive/high nestin vs. negative/low nestin: OR = 2.17, 95% CI = 1.26–3.72, P = 0.005). For the analysis stratified by cancer category, three articles that included 87 cases and 207 controls were used to evaluate the relationship between nestin and lung cancer (median or advanced stage vs. early stage). As show in Figure 5, the main effect remained in studies of lung cancer (positive/high nestin vs. negative/low nestin: OR = 2.00, 95% CI = 1.16–3.44, P = 0.01).

More importantly, regarding to focus at the association of nestin with lung cancer staging, as shown in Figure 6, we have done some analysis on the relationship between nestin and T staging or N staging. In the analysis stratified by T staging (T1-2 vs. T3-4) in lung cancer, the main effect remained (positive/high nestin vs. negative/low nestin: OR = 3.73, 95% CI = 1.42–9.74, P = 0.007). Meanwhile, in the analysis stratified by N staging (N0 vs. N1-3) in lung cancer, the main effect remained (positive/high nestin vs. negative/low nestin: OR = 2.73, 95% CI = 1.39–5.37, P = 0.004).

Tests of heterogeneity

Tests of heterogeneity between trials using the Q statistic showed no significant heterogeneity in the following analyses: nestin expression with cancer staging (positive/high nestin vs. negative/low nestin, P = 0.76,
\( I^2 = 0\% \), nestin expression with lymph node positivity (positive/high nestin vs. negative/low nestin \( P = 0.67, I^2 = 0\% \)), and nestin expression with lung cancer stage, positive/high nestin vs. negative/low nestin \( P = 0.98, I^2 = 0\% \). Accordingly, data were analyzed using a fixed-effects model.

**Publication bias**

Funnel plots were performed to assess publication bias. As show in Figure 3, the funnel plots revealed no obvious asymmetry at any cancer stage (median or advanced stage vs. early stage), and the results revealed no publication bias \( P > 0.05 \).

**DISCUSSION**

TNM stage is determined according to the outcomes of physical examination, biopsy, and imaging tests; in clinical application, a pathological report is the basis of TNM staging.[27] In addition to anatomic tumor categories, most sites and tumor types are...
Figure 2: Forest plots of nestin and median/advanced cancer stage among all cases (positive/high nestin vs. negative/low nestin). The squares and horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

Figure 3: Funnel plot assessing evidence of publication bias from seven studies (median or advanced stage vs. early stage).

Figure 4: Forest plots of nestin and lymph node involvement among all cases (N_{1,2} vs. N_0). The squares and horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
classified according to TNM stage, with the anatomic extent of the tumor determining the cancer stage.\cite{1, 2} Clearly distinguishing between stages and reliably estimating survival probability require that each stage be homogeneous. Stages I to III correspond to progressively advanced localized and regional cancer, whereas stage IV corresponds to systemic metastases. An accurate staging system is important for guiding physicians in treatment options and determining patients’ prognosis.\cite{28}

Nestin was initially discovered based on its expression in neural progenitor cells, where it was considered a marker for distinguishing precursor cells from differentiated cells.\cite{29, 30} Subsequent reports have shown that nestin is expressed in breast, prostate and pancreatic cancer, and is positively correlated with tumor malignancy.\cite{31-33} But some findings regarding nestin are inconclusive or controversial, especially in the context of cancer staging.

Although a number of studies investigating the association of nestin with cancer stage have been

**Figure 5:** Forest plots of nestin and lung cancer stage in three cases (median or advanced stage vs. early stage). The squares and horizontal lines correspond to the study-specific OR and 95% CI, respectively. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.

**Figure 6:** A. Forest plots of nestin and T staging of lung cancer in two cases (T\textsubscript{3-4} vs. T\textsubscript{1-2}). B. Forest plots of nestin and N staging of lung cancer in two cases (N\textsubscript{1-2} vs. N\textsubscript{0}). The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight (inverse of the variance). The diamond represents the summary OR and 95% CI.
reported, only one clinical study by Karsten et al. demonstrated a significant relationship between high nestin levels and cancer stage.[24] Our aim here was to clarify the relationship between nestin and cancer stage by performing a meta-analysis of the literature in the field. This analysis provided evidence of an association between positive/high nestin and median/advanced cancer stage in different cancers, demonstrating a significant main effect of positive/high nestin versus negative/low nestin. Analyses of nestin association stratified according to lymph node involvement (N\textsubscript{1-2} vs. N\textsubscript{0}) and cancer category were also statistically significant.

The relationships established here suggest that positive/high nestin can be used as an added factor in determining TNM stage and judging cancer malignancy, especially for lung cancer. Regarding to focus at the association of nestin with lung cancer staging, we have done some analysis on the relationship between nestin and T staging or N staging. Analyses of nestin association stratified according to T staging (T\textsubscript{3-4} vs. T\textsubscript{1-2}) or N staging (N\textsubscript{1-2} vs. N\textsubscript{0}) and lung cancer category were also statistically significant. This analysis provided evidence of an association between positive/high nestin and median/advanced cancer stage in lung cancer, demonstrating a significant main effect of positive/high nestin versus negative/low nestin. Further investigations of nestin and lung cancer stage on a larger scale are needed to verify this result and firmly establish nestin as a cancer malignancy biomarker.

Some limitations of this meta-analysis should be noted. Firstly, this meta-analysis was based on pooled positive or high nestin data; thus, we were only able to address the relationship between positive/high nestin and cancer stage, and not individual positive or high-nestin values. Secondly, a small-study effect, in which results reported in smaller studies have a disproportionate effect on the final analysis, could not be avoided because of the relatively small size of some of the studies. Ultimately, additional large scale-studies with more detailed individual data are warranted to further validate the relationship of nestin with cancer stage.

### CONCLUSIONS

In summary, our meta-analysis provides evidence of an association between positive/high nestin and cancer stage, suggesting that knowledge of nestin expression status could facilitate cancer staging, especially in lung cancer.

### MATERIALS AND METHODS

#### Publication search

Relevant articles published as of June 2014 were retrieved from multiple databases, including PubMed, ISI Web of Knowledge, Embase, and the Chinese National Knowledge Infrastructure (CNKI) using the keywords nestin, malignancy, neoplasm, cancer staging and TNM staging. Articles with case-control or cohort studies related to the association of positive/high nestin and cancer staging were collected.

#### Inclusion criteria

The following criteria were used to select publications for further meta-analysis: (1) published in English or Chinese, regardless of publication date; (2) evaluated associations between positive/high nestin and cancer stage; (3) confirmed cancer patients pathologically; (4) included detailed cancer/TNM staging data; and (5) contained at least two comparison groups (positive-nestin group vs. negative-nestin group, or high-nestin group vs. low-nestin group).

#### Data collection

Publication details such as the first author’s name, publication year, patients’ country of origin and ethnicity, total number of patients, cancer type, median/mean age of the study population, and disease stage were collected.
for each eligible publication. Positive or high nestin and cancer/TNM stage were end points of interest.

**Statistical analysis**

Patients were divided into positive/high nestin and negative/low nestin groups, and the associations between positive/high nestin and cancer stage were measured by determining odds ratios (ORs) with 95% confidence intervals (CIs). The significance of pooled ORs was determined by the Z test. Statistical heterogeneity among studies was assessed using Q and $I^2$ statistics, where variation due to heterogeneity or random error identified with Q tests were further defined according to $I^2$ values, as follows: $I^2 = 0–25\%$, no heterogeneity; $I^2 = 25–50\%$, moderate heterogeneity; $I^2 = 50–75\%$: large heterogeneity; and $I^2 = 75–100\%$, extreme heterogeneity.[26] A fixed-effects model was applied in the initial analysis, and if significant heterogeneity existed, a confirmed random-effects model was used. Publication bias was evaluated using funnel plots. All statistical analyses were carried out with Review Manager version 5.0 (Revman; The Cochrane Collaboration, Oxford, UK). All $P$-values in the meta-analysis were two-sided, and a $P$-value < 0.05 was considered significant.

**ACKNOWLEDGMENTS**

This study was supported by grants from the National Natural Science Foundation of China (No. 81101774).

**COMPETING INTERESTS**

The authors declare that they have no competing interests.

**Authors’ contributions**

BZ, TW, and ZG conceived and designed the study, and participated in selecting literature reports, extracting data, performing statistical analyses and drafting the manuscript. JZ, FZ, RH, XZ, and WY were involved in critically assessing and revising the intellectual content of the manuscript. All authors read and approved the final manuscript.

**REFERENCES**

1. Sobin LH. TNM: evolution and relation to other prognostic factors. Semin Surg Oncol 2003; 21: 3-7.
2. TNM Classification of Malignant Tumors. 5th ed. Wiley: New York, 1997.
3. Guérette D, Khan PA, Savard PE, Vincent M (2007). “Molecular evolution of type VI intermediate filament proteins”. BMC Evol Biol. 7: 164. doi:10.1186/1471-2148-7-164.
4. Cattaneo E and McKay R. Proliferation and differentiation of neuronal stem cells regulated by nerve growth factor. Nature 1990; 347: 762 - 765.
5. Lendahl U, Zimmerman LB, McKay RD. CNS stem cells express a new class of intermediate filament protein. Cell 1990, 60: 585-595.
6. Park D, Xiang AP, Mao FF, Zhang L, Di CG, Liu XM, Shao Y, Ma BF, Lee JH, Ha KS, Walton N, Lahn BT. Nestin is required for the proper self-renewal of neural stem cells. Stem Cells 2010; 28: 2162-2171.
7. Shimizu T, Sugawara K, Tosaka M, Imai H, Hoya K, Takeuchi T, Sasaki T, Saito N. Nestin expression in vascular malformations: a novel marker for proliferate endothelium. Neurol Med Chir(Tokyo) 2006; 46: 111-117.
8. Takakuwa U, Maeno K, Kunii E, Ozasa H, Hijiikata H, Uemura T, Kasai D, Ohkubo H, Miyazaki M, Oguri T, Niimi A. Involvement of intermediate filament nestin in cell growth of small-cell lung cancer. Lung cancer 2013; 81: 174-179.
9. Amoh Y, Yang M, Li L, Reynoso J, Bouvet M, Moossa AR, Katsuoka K, Hoffman RM. Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis. Cancer Res 2005; 65: 5352-5357.
10. Xue XJ, Yuan XB. Nestin is essential for mitogen-stimulated proliferation of neural progenitor cells. Mol Cell Neurosci 2010; 45: 26-36.
11. K. Krüger, I.M. Stefansson, K. Collett, J.B. Arnes, T. Aas, L.A. Akslen. Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer. Breast 2013; 22: 282-288.
12. Jimeno A, Feldmann G, Suárez-Gauthier A, Rasheed Z, Solomon A, Zou GM, Rubio-Viqueira B, García-García E, López-Rios F, Matsui W, Maitra A, Hidalgo M. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009; 8: 310-314.
13. Bentivegna A, Conconi D, Panzeri E, Sala E, Bovo G, Viganò P, Brunelli S, Bossi M, Tredici G, Strada G, Dalprà L. Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci 2010; 101: 416-424.
14. Singh SK, Clarke ID, Hide T, Dirks PB. Cancer stem cells in nervous system tumors. Oncogene 2004; 23: 7267-7273.
15. Bortolomai I, Canevari S, Facetti I, De Cecco L, Castellano G, Zacchetti A, Alison MR, Miotti S. Tumor initiating cells: Development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle 2010; 9: 1194-1206.
16. Okuno K, Ohta S, Kato H, Taga T, Sugita K, Takeuchi Y. Expression of neural stem cell markers in malignant
rhabdoid tumor cell lines. Oncol Rep 2010; 23: 485-492.

17. Hombach-Klonisch S, Paranjothy T, Wiechee E, Pocar P, Mustafa T, Seifert A, Zahl C, Gerlach KL, Biemann K, Steger K, Hoang-Yu C, Schulze-Osthoff K, Los M. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Arch Immunol Ther Exp (Warsz) 2008; 56: 165-180.

18. Kasper S. Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 2008; 4: 193-201.

19. Guzmán-Ramírez N, Völler M, Wetterwald A, Germann M, Cross NA, Rentsch CA, Schalken J, Thalmann GN, Cecchini MG. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate 2009; 69: 1683-1693.

20. Kawamoto M, Ishiwata, T, Cho K, Uchida E, Korc M, Naito Z, Tajiri T. Nestin expression correlates with nerve and retroperitoneal tissue invasion in pancreatic cancer. Hum Pathol 2009; 40: 189-198.

21. Ryuge S, Sato Y, Wang G, Matsumoto T, Jiang S, Katono K, Inoue H, Satoh Y, Masuda N. Prognostic significance of Nestin expression in resected non-small cell lung cancer. Chest 2011; 139: 862-869.

22. Chen Z, Wang T, Luo H, Lai Y, Yang X, Li F, Lei Y, Su C, Zhang X, Lahn BT, Xiang AP. Expression of nestin in lymph node metastasis and lymphangiogenesis in non-small cell lung cancer patients. Human Pathology 2010; 41: 737-744.

23. Chet Z, Wang J, Cai L, Zhong B, Luo H, Hao Y, Yu W, Wang B, Su C, Lei Y, Bella AE, Xiang AP, Wang T. Role of the stem cell-associated intermediate filament Nestin in malignant proliferation of non-small cell lung cancer. PLoS ONE 9: e85584.

24. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. Proliferation of immature tumor vessels is a novel marker of clinical progression in prostate cancer. Cancer Res 2009; 69: 4708-4715.

25. Zhao Y, Han Y, Zhang L, Wang Y, Ma Y, Zhang F, Fu D, Wang X. Quantitative assessment of the effect of cytochrome P450 2C9 gene polymorphism and colorectal cancer. PLoS ONE 2013; 8: e60607.

26. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.

27. Society AC: AJCC Cancer Staging Manual-Fifth Edition. Lippincott-Raven; 1997.

28. Wallin E and Heijne GV. Genome-wide analysis of integral membrane proteins from eubacterial, archaeal, and eukaryotic organisms. Protein Sci 1998; 7: 1029-1038.

29. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, Koniecek S, Hon J, Marshall M, Graff JR. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004; 10: 3448-3456.

30. Wang Q, Zeng YJ, Huo P, Hu JL, Zhang JH. A specialized plug-in software module for computer-aided quantitative measurement of medical images. Med Eng Phys 2003; 25: 887-892.

31. Ohike N, Sato M, Hisayuki T, Imataka H, Sato S, Wada Y, Saito K, Takahashi M, Tajiri T, Kunimura T, Morohoshi T. Immunohistochemical analysis of Nestin and c-kit and their significance in pancreatic tumors. Pathol Int 2007; 57: 589-593.

32. Wiese C, Rolletschek A, Kania G, Blyszczuk P, Tarasov KV, Tarasova Y, Wersto RP, Boheler KR, Wobus AM. Nestin expression: a property of multi-lineage progenitor cells? Cell Mol Life Sci 2004; 61: 2510-2522.

33. Suzuki S, Namiki J, Shibata S, Mastuzaki Y, Okano H. The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. J Histochem Cytochem 2010; 58: 721-730.